Last reviewed · How we verify
Hippuran I131 — Competitive Intelligence Brief
unknown
iodohippurate sodium I131
Nephrology
Live · refreshed every 30 min
Target snapshot
Hippuran I131 (iodohippurate sodium I131). Hippuran I131 works by being taken up by the kidneys and excreted in the urine, allowing for imaging of the renal function.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Hippuran I131 TARGET | iodohippurate sodium I131 | unknown | iodohippurate sodium I131 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (iodohippurate sodium I131 class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Hippuran I131 CI watch — RSS
- Hippuran I131 CI watch — Atom
- Hippuran I131 CI watch — JSON
- Hippuran I131 alone — RSS
- Whole iodohippurate sodium I131 class — RSS
Cite this brief
Drug Landscape (2026). Hippuran I131 — Competitive Intelligence Brief. https://druglandscape.com/ci/iodohippurate-sodium-i131. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing